Baird Capital announced today that its venture team has completed an investment in Jumpcode Genomics ("Jumpcode"), a genome technology company focused on improving the understanding of human disease. Joining Baird Capital in the $21 million Series B round of funding was Arboretum Ventures and existing investor LYZZ Capital. 

Founded in 2016, Jumpcode's patented technology unlocks the power of next-generation sequencing by improving sensitivity, reducing costs, simplifying workflows and removing bias. Researchers worldwide are using Jumpcode's CRISPRClean technology in the fields of basic research, infectious disease, oncology and consumer genomics. 

"The Jumpcode Genomics team and advisors have a tremendous amount of experience and knowledge in this sector," said Mike Liang, Partner with Baird Capital. "We believe the underlying technology within Jumpcode has revolutionary applications within the life sciences tools market and within clinical diagnostic applications."